Blueberry NFT, Repure Life Sciences and Solidarity Severance Hospital to discover ‘Corona 19 cure biomarkers’
[아시아경제 유현석 기자] Blueberry NFT announced on the 27th that Repure Life Sciences and Yonsei University Severance Hospital have discovered a ‘Corona 19 cure biomarker’.
In June of last year, Blueberry NFT, Repure Life Sciences, and Yonsei University Severance Hospital started joint research with the goal of developing an antibody treatment derived from the plasma of a person who has recovered from COVID-19. On the 26th, the results of this research were jointly applied for a patent.
The results of this study used the latest omics analysis and bioinformatics on plasma samples from the blood of the non-COVID-19 normal control group and the recovered group who were judged to be cured after being infected with COVID-19. Proteins specifically detectable in the plasma of the recovered group after COVID-19 infection were identified compared to the non-infected control group. Through this, protein biomarkers necessary for infection diagnosis and treatment prognosis were discovered.
In the study, omics analysis was performed using plasma samples from the non-infected control group and from the recovery group after COVID-19 infection, and the results were analyzed using bioinformatics. Based on this, we found that the non-infected control group and the group recovered after Corona 19 infection can be sufficiently distinguished from the non-infected control group by extracting quantitative and qualitative information on plasma proteins, performing additional statistical analysis, and comparing the quantitative differences in plasma proteins.
Using the quantitative information of the identified proteins, 9 proteins (3 increased proteins, 6 decreased proteins in the recovery group) were derived that were statistically significant between the two groups and had an increase or decrease more than 2 times. The derived nine proteins specific to the COVID-19 recovery group are expected to be used as biomarkers that can monitor the treatment efficacy in the treatment process after infection, the research team explained.
A company official said, “If we further study the relevance of these proteins to COVID-19, it is expected that they can be used as targets for the development of preventive and additional therapeutic agents in the future.” We are currently preparing a thesis for publication in overseas academic journals,” he said.
Reporter Hyun-seok Yoo [email protected]